EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed

An FDA committee of experts this summer voted overwhelmingly against approval of AstraZeneca's ($AZN) new ovarian cancer treatment, which it will market as Lynparza. But reviewers for the EMA like it enough to give it a recommendation nod for use on patients with platinum-sensitive ovarian cancer and BRCA mutations, FierceBiotech reports. AstraZeneca pegged peak earnings for the drug at $2 billion when it was tossing around reasons not to accept a buyout bid from Pfizer ($PFE). Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.